702 related articles for article (PubMed ID: 26232241)
1. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
[TBL] [Abstract][Full Text] [Related]
3. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R
Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670
[TBL] [Abstract][Full Text] [Related]
4. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Steen Andersen H; Eramo A; Hansen K; Naber D
Int Clin Psychopharmacol; 2017 May; 32(3):147-154. PubMed ID: 28252452
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
7. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Ettrup A; Eramo A; Hansen K; Naber D
PLoS One; 2017; 12(8):e0183475. PubMed ID: 28837593
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.
Sapin C; Hartry A; Kamat SA; Beillat M; Baker RA; Eramo A
Drugs Context; 2016; 5():212301. PubMed ID: 27708677
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
20. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
